Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

Inclusion Criteria: * Subjects with Probable Alzheimer's disease * Mini-Mental State Examination (MMSE) score of 14 to 24 inclusive at screening and a CDR-SB score ≥2 at the screening assessment * Modified Hachinski Ischemic Score (mHIS) ≤4 at screening * Female subjects are ≥1 year post-menopausal or are surgically sterile * Caregiver available; if not living in the same household, caregiver sees subject at least four times each week * Subject living at home, senior residential setting, or an institutional setting without the need for continuous nursing care * General health status acceptable for participation in a 24 week clinical trial be administered Exclusion Criteria: General * Participation in another therapeutic clinical trial within 30 days before Baseline * Prior participation in an amyloid vaccination clinical study * Inability to swallow capsules * Likely inability to complete 24 week study * Inability to be ≥75% compliant with single-blind placebo run-in medication * Inability to adequately perform cognitive tests * History of significant cardiovascular disease * Major depression * Psychosis * History of stroke within 18 months of screening * Head trauma * Inability to perform any screening or baseline evaluations